PO.BCS01.14 · 生物信息与计算
评估变异检出流程对从头SBS突变特征提取的影响
Assessing the Impact of Variant Calling Pipelines on De Novo SBS Mutational Signature Extraction
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
解析肿瘤基因组中的突变过程(即突变特征)可为癌症病因和演化提供关键洞见。然而,上游变异检出策略如何传播并影响从头特征提取的准确性仍研究不足。在此,我们利用来自癌症基因组图谱(The Cancer Genome Atlas)的8,900余份全外显子组序列和来自全基因组泛癌分析(Pan-Cancer Analysis of Whole Genomes)研究的1,800份全基因组,系统评估突变检出算法如何影响单碱基替换(SBS)特征分析。我们证明,一致性变异检出策略在不同参考基因组和流程版本间可产生高度稳定的突变特征。相比之下,单个变异检出工具会引入系统性的假阳性突变,表现为稳定的、人为的特征,可被三种特征提取工具检测到。一种最简一致性方法(仅要求两个变异检出工具达成一致)成功消除了技术性特征,同时保留了真实的生物学信号,对于高SBS突变上下文分析尤为重要。我们的发现确立了一致性变异检出对稳健突变特征分析的必要性,并提供了区分生物学过程与技术性假象的清晰框架。
查看英文原文 English abstract
Deconstructing the mutational processes in a tumor's genome, known as mutational signatures, provides critical insights into cancer etiology and evolution. However, how the upstream variant-calling strategies propagate to affect the accuracy of de novo signature extraction remains underexplored. Here, we systematically evaluate how mutation-calling algorithms influence single-base substitution (SBS) signature analysis using over 8,900 whole-exome sequences from The Cancer Genome Atlas and 1,800 whole genomes from the Pan-Cancer Analysis of Whole Genomes study. We demonstrate that consensus variant-calling strategies produce remarkably stable mutational signatures across different reference genomes and pipeline versions. In contrast, individual variant callers introduce systematic false-positive mutations that manifest as stable, artifactual signatures, detectable by three signature extraction tools. A minimal consensus approach, requiring agreement between just two variant callers, successfully eliminates technical signatures while preserving genuine biological signals and is especially important for high SBS mutational context analysis. Our findings establish consensus variant calling as essential for robust mutational signature analysis and provide a clear framework for distinguishing biological processes from technical artifacts.
利益披露 Disclosure
Z. Jiang, None..
J. N. Au, None..
M. Kazachkova, None..
M. Díaz-Gay, None..
R. Vangara, None.
L. B. Alexandrov,
io9 (Acurion) Other, Hold equity and receive income.
Inocras Other, Compensated member of the scientific advisory board.
Hologic, Inc. Other, Spouse is an employee.